(LYMS) Nasdaq-100 II Acc EUR - Overview
Etf: Growth, Technology, Non-Cyclical, Services, Communication
| Risk 5d forecast | |
|---|---|
| Volatility | 20.0% |
| Relative Tail Risk | 0.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | -6.44 |
| Character TTM | |
|---|---|
| Beta | 0.285 |
| Beta Downside | 0.483 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.74% |
| CAGR/Max DD | 0.91 |
Description: LYMS Nasdaq-100 II Acc EUR January 10, 2026
The Amundi Nasdaq-100 II UCITS ETF Acc EUR (ticker LYMS) is a Germany-domiciled exchange-traded fund that tracks the Morningstar US Large-Cap Growth (Non-Real-Estate) Index, effectively replicating the performance of the Nasdaq-100’s growth-oriented constituents in EUR-denominated accumulating shares.
Key data points (as of the latest public filings): • Net assets ≈ €2.1 bn, indicating solid investor demand for a Europe-listed Nasdaq-100 exposure. • Expense ratio 0.30 % (annual), competitive within the US-large-cap growth ETF space. • Top sector weightings: Technology (~45 %), Consumer Discretionary (~20 %) and Healthcare (~12 %), reflecting the index’s reliance on high-growth tech firms that are sensitive to US monetary-policy cycles and corporate-earnings momentum.
Given the ETF’s heavy tech tilt, its performance is closely linked to macro drivers such as US Federal Reserve policy, semiconductor supply-chain dynamics, and corporate-profit growth trends in the cloud-computing and AI sectors.
For a deeper, data-driven assessment of LYMS’s risk-adjusted returns and how it fits into a diversified growth portfolio, you might explore the analytical tools on ValueRay.
What is the price of LYMS shares?
Over the past week, the price has changed by -2.77%, over one month by -3.86%, over three months by -3.25% and over the past year by +1.00%.
Is LYMS a buy, sell or hold?
What are the forecasts/targets for the LYMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 101 | 17.1% |
LYMS Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 4.63b EUR (4.63b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 4.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 4.63b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.97% (E(4.63b)/V(4.63b) * Re(6.97%) + (debt-free company))
Discount Rate = 6.97% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)